Covid-19 roundup: Buoyed by soaring shares, Novavax inks a $167M deal to buy Covid-19 vaccine-making facility; France cools on hydroxychloroquine
The pandemic has offered the best news Novavax has had in years. Its stock price is trading at 7x the pre-panic levels with a Covid-19 vaccine in the mix, as investors buy anything that moves in that field, and they’re flush to carve out their own pathway on the manufacturing front.
Wednesday morning Novavax reported that they are spending $167 million on the Czech-based Praha Vaccines, bagging a manufacturing facility along the way.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,300+ biopharma pros reading Endpoints daily — and it's free.